These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21092287)

  • 1. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.
    Garcia-Garcia I; Gonzalez-Delgado CA; Valenzuela-Silva C; Hernandez-Bernal F; Ferrero-Bibilonia J; Soto-Hernandez R; Cervantes-Llano M; Ducongé J; Correa-Fernandez A; Olivera-Ruano L; Lopez-Saura P
    Drugs R D; 2004; 5(5):271-80. PubMed ID: 15357626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
    Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
    Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
    García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
    BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.
    Costa MB; Picon PD; Sander GB; Cuni HN; Silva CV; Meireles RP; Góes ACMA; Batoreu NM; Maia MLS; Albuquerque EM; Matos DCS; Saura PL
    BMC Pharmacol Toxicol; 2018 Jan; 19(1):1. PubMed ID: 29301580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
    Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G
    J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
    Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
    Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
    De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
    J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.
    Bruno R; Sacchi P; Scagnolari C; Torriani F; Maiocchi L; Patruno S; Bellomi F; Filice G; Antonelli G
    Aliment Pharmacol Ther; 2007 Aug; 26(3):369-76. PubMed ID: 17635371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study.
    Patel TB; Pequignot E; Parker SH; Leavitt MC; Greenberg HE; Kraft WK
    Int J Clin Pharmacol Ther; 2007 Mar; 45(3):161-8. PubMed ID: 17416111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.
    Nieforth KA; Nadeau R; Patel IH; Mould D
    Clin Pharmacol Ther; 1996 Jun; 59(6):636-46. PubMed ID: 8681488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
    Foster GR
    Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Thompson J; Gurney H; Selby P; Figlin R; Negrier S; Ernst S; Siebels M; Ginsberg M; Rittweger K; Hooftman L
    Ann Oncol; 2002 Nov; 13(11):1799-805. PubMed ID: 12419754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men.
    Jung YS; Chae D; Park K
    J Pharm Sci; 2018 Dec; 107(12):3171-3178. PubMed ID: 30179597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
    J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.